Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

Transplantation - Tập 81 Số 10 - Trang 1390-1397 - 2006
Olle Ringdén1,2,3, Mehmet Uzunel1,2, Ida Rasmusson2, Mats Remberger1,2, Berit Sundberg1,2, Helena Lönnies1,2, Hanns‐Ulrich Marschall4, Aldona Dlugosz4, Attila Szakos5, Zuzana Hassan1, Brigitta Omazic1,2, J Aschan1, Lisbeth Barkholt1, Katarina Le Blanc1,2
1Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
2Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
3Olle Ringdén, M.D., Ph.D., Division of Clinical Immunology, F79 Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden.
4Department of Gastroenterology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
5Division of Pathology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thomas, 1977, One hundred patients with acute leukaemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation., Blood, 49, 511, 10.1182/blood.V49.4.511.511

Barrett, 1989, Marrow transplantation for acute lymphoblastic leukaemia: Factors affecting relapse and survival., Blood, 74, 862, 10.1182/blood.V74.2.862.862

Appelbaum, 2003, The current status of hematopoietic cell transplantation., Annu Rev Med, 54, 491, 10.1146/annurev.med.54.101601.152456

Ringdén, 1997, Allogeneic bone marrow transplantation for hematological malignancies - controversies and recent advances., Acta Oncol, 36, 549, 10.3109/02841869709001316

Storb, 1985, Graft-versus-host disease in dog and man: the Seattle experience., Immunol Rev, 88, 215, 10.1111/j.1600-065X.1985.tb01160.x

Ringdén, 1985, Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy., Transplantation, 40, 39, 10.1097/00007890-198507000-00009

Martin, 1990, A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment., Blood, 76, 1464, 10.1182/blood.V76.8.1464.1464

Weisdorf, 1990, Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome., Blood, 75, 1024, 10.1182/blood.V75.4.1024.1024

Aschan, 1994, Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis., Bone Marrow Transplant, 14, 601

Herve, 1990, Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10)., Blood, 75, 1017, 10.1182/blood.V75.4.1017.1017

Anasetti, 1994, Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor., Blood, 84, 1320, 10.1182/blood.V84.4.1320.1320

McCarthy, 1996, A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease., Transplantation, 62, 626, 10.1097/00007890-199609150-00015

Benito, 2001, Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease., Transplantation, 72, 1924, 10.1097/00007890-200112270-00010

Kobbe, 2001, Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody., Bone Marrow Transplant, 28, 47, 10.1038/sj.bmt.1703094

Remberger, 2001, Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin., Clin Transplant, 15, 147, 10.1034/j.1399-0012.2001.150301.x

Deeg, 2002, Treatment of steroid-refractory acute graft-versus-host disease with anti-CD 147 monoclonal antibody ABX-CBL., Blood, 98, 2052, 10.1182/blood.V98.7.2052

Couriel, 2004, Tumor necrosis factor-a blockade for the treatment of acute GvHD., Blood, 104, 649, 10.1182/blood-2003-12-4241

Friedenstein, 1968, Heterotypic transplants of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues., Transplantation, 6, 230, 10.1097/00007890-196803000-00009

Prockop, 1997, Marrow stromal cells as stem cells for nonhematopoietic tissues., Science, 276, 71, 10.1126/science.276.5309.71

Pittenger, 1999, Multilineage potential of human mesenchymal stem cells., Science, 284, 143, 10.1126/science.284.5411.143

Liechty, 2000, Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep., Nat Med, 6, 1282, 10.1038/81395

Almeida-Porada, 2000, Co-transplantation of human stromal cell progenitors into pre-immune fetal sheep results in an early appearance of human donor cells in circulation and boosts cell levels in bone marrow at a later timepoint after transplantation., Blood, 95, 3620, 10.1182/blood.V95.11.3620

Angeloupoulou, 2003, Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice., Exp Hematol, 31, 413, 10.1016/S0301-472X(03)00042-0

Noort, 2002, Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice., Exp Hematol, 30, 870, 10.1016/S0301-472X(02)00820-2

Maitra, 2004, Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation., Bone Marrow Transplant, 33, 597, 10.1038/sj.bmt.1704400

Tse, 2003, Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation., Transplantation, 75, 389, 10.1097/01.TP.0000045055.63901.A9

Le Blanc, 2003, HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells., Exp Hematol, 31, 890, 10.1016/S0301-472X(03)00110-3

Klyushnenkova, 2005, T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression., Biomed Science, 12, 47, 10.1007/s11373-004-8183-7

Rasmusson, 2003, Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells., Transplantation, 76, 1208, 10.1097/01.TP.0000082540.43730.80

Le Blanc, 2005, Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta., Transplantation, 79, 1607, 10.1097/01.TP.0000159029.48678.93

Kampera, 2003, Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide., Blood, 101, 3722, 10.1182/blood-2002-07-2104

Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo., Exp Hematol, 30, 42, 10.1016/S0301-472X(01)00769-X

Di Nicola, 2002, Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli., Blood, 99, 3838, 10.1182/blood.V99.10.3838

Le Blanc, 2003, Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility system., Scand J Immunol, 57, 11, 10.1046/j.1365-3083.2003.01176.x

Maccario, 2005, Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype., Haematologica, 90, 516

Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haplo-identical mesenchymal stem cells., Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7

Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use., Bone Marrow Transplant, 16, 557

Koç, 2000, Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy., Clin Oncol, 18, 307

Horwitz, 2002, Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone., Proc Natl Acad Sci USA, 99, 8932, 10.1073/pnas.132252399

Koç, 2002, Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)., Bone Marrow Transplant, 30, 215, 10.1038/sj.bmt.1703650

Ringdén, 1999, Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busulfan compared to total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia., Blood, 93, 2196, 10.1182/blood.V93.7.2196

Slavin, 1998, Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases., Blood, 91, 756, 10.1182/blood.V91.3.756

Hentschke, 2003, Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma., Bone Marrow Transplant, 31, 253, 10.1038/sj.bmt.1703811

McSweeney, 2001, Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects., Blood, 97, 3390, 10.1182/blood.V97.11.3390

Ringdén, 1995, Similar incidence of graft-versus-host disease using HLA-A, -B and –DR identical unrelated bone marrow donors as with HLA-identical siblings., Bone Marrow Transplant, 15, 619

Storb, 1989, Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: long-term follow-up of a controlled trial., Blood, 73, 1729, 10.1182/blood.V73.6.1729.1729

Olerup, 1992, HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation., Tissue Antigens, 39, 225, 10.1111/j.1399-0039.1992.tb01940.x

Lennon, 1996, Development of a serum screen for mesenchymal progenitor cells from bone marrow., In vitro Cell Dev Biol Anim, 32, 602, 10.1007/BF02724045

Mattsson, 2001, Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation., Leukemia, 15, 1976, 10.1038/sj.leu.2402311

Gustafsson, 2000, Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells., Blood, 95, 807, 10.1182/blood.V95.3.807.003k24_807_814

Le Blanc, 2005, Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation., Biol Blood Marrow Transplant, 11, 321, 10.1016/j.bbmt.2005.01.005

Rasmusson, 2005, Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigen by different mechanisms., Exp Cell Res, 305, 33, 10.1016/j.yexcr.2004.12.013

Aggarwal, 2005, Human mesenchymal stem cells modulate allogeneic immune cell responses., Blood, 105, 1815, 10.1182/blood-2004-04-1559

Ringdén, 1990, Hematology Vol. 12: Graft-versus-host disease. Immunology, Pathophysiology, and Treatment., 467

Gao, 2001, The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion., Cells Tissues Organs, 169, 12, 10.1159/000047856

Fouillard, 2003, Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma., Leukemia, 17, 474, 10.1038/sj.leu.2402786